SlideShare a Scribd company logo
1 of 42
Analysis and Interpretation: Overview ,[object Object],[object Object],[object Object],[object Object],[object Object]
Framework for synthesis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Why Perform a Meta-analysis? ,[object Object],[object Object],[object Object],[object Object],[object Object]
More on Meta-analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]
When not Appropriate to do M/a ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dichotomous Measures ,[object Object],[object Object],[object Object],[object Object]
Risk ratio (RR)  aka relative risk RR =   a / (a+b)  c / (c+d) Risk/ probability/ chance  of the occurrence of an event in treatment relative to control Intervention Control a+b=n I c+d=n C Event No event d c b a
Sample RR Calculation Death No death RR =   14/133  =  0.11  = 0.13 128/148  0.86 Drug 133 148 Placebo 20 128 119 14
Odds ratio (OR) Intervention Control No event Event OR =  a / b  c / d  Odds of an event occurring to it not occurring for treatment relative to control a+b=n I c+d=n C d c b a
Sample OR Calculation Death No death Drug Placebo 133 148 OR =   14/119  =  0.12  = 0.019 128/20  6.4 20 128 119 14
Interpreting (for intervention) Increased odds (harmful) Increased odds  (beneficial) OR>1 (6.4/0.12) Reduced odds (beneficial) Reduced odds (not beneficial) OR<1 (0.12/6.4) No difference No difference OR=1, RR=1 Increased risk (harmful) Increased risk  (beneficial) RR>1 (0.86/0.11) Reduced risk  (beneficial) Reduced risk (not beneficial) RR<1 (0.11/0.86) Bad outcome  (e.g. infection) Good outcome (e.g. remission)
RR vs. OR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Closer Look at Odds RR = 0.11 / 0.86 = 0.13 ↑ A rate (11%) OR = 0.12 / 6.4  = 0.019 ↑ ~1:9 ↑ ~7:1
Absolute Effect Measures ,[object Object],[object Object]
Risk Difference (RD) Death No death Actual difference in  risk of events Placebo Drug 133 148 RD = 14/133 – 128/148 = 0.11 – 0.86 = - 0.75 20 128 119 14
Risk Difference (RD)  (continued) ,[object Object],[object Object],[object Object]
NNT ,[object Object],[object Object],[object Object],[object Object],[object Object]
Uncertainty ,[object Object],[object Object],[object Object],[object Object]
Which effect measure for meta-analysis? ,[object Object],[object Object],[object Object]
Meta-analysis in RevMan
Meta-analysis in RevMan  (continued) ,[object Object],[object Object]
Fixed vs Random Effects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fixed Effects Analysis in Picture View
Random Effects Analysis in Picture View
Random effects in RevMan 5 ←  DerSimonian and Laird  random effects model
Random effects in RevMan 5  (continued) ←  DerSimonian and Laird  random effects model
Sample Forest plot (RR) ,[object Object]
Meta-analysis for Continuous Data ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Mean Difference (MD) ,[object Object],[object Object]
Standardized Mean Difference (SMD) ,[object Object]
Heterogeneity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
    Clinical and Methodologic Heterogeneity  ,[object Object],[object Object],[object Object]
Statistical Heterogeneity ,[object Object],[object Object]
Q test ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I 2  Statistic ,[object Object],[object Object],[object Object]
I 2  Statistic  (continued) * Importance of I 2  value depends on: ●  magnitude and direction of effects ●  strength of evidence of heterogeneity - Chi-squared P value, or - I 2  confidence interval Considerable heterogeneity*  75% to 100% May represent substantial heterogeneity* 50% to 90% May represent moderate heterogeneity* 30% to 60% Might not be important 0% to 40% Guide to Interpretation I 2  value
Sample Forest Plot:  Q and I 2
What to do with (Statistical) Heterogeneity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What to do with (Statistical) Heterogeneity ,[object Object],[object Object],[object Object],[object Object]
Subgroup and Meta-regression ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Subgroup Analysis
Sensitivity Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Confounding and Directed Acyclic Graphs
Confounding and Directed Acyclic GraphsConfounding and Directed Acyclic Graphs
Confounding and Directed Acyclic GraphsDarren L Dahly PhD
 
Meta analysis ppt
Meta analysis pptMeta analysis ppt
Meta analysis pptSKVA
 
Metanalysis Lecture
Metanalysis LectureMetanalysis Lecture
Metanalysis Lecturedrmomusa
 
Bias, confounding and fallacies in epidemiology
Bias, confounding and fallacies in epidemiologyBias, confounding and fallacies in epidemiology
Bias, confounding and fallacies in epidemiologyTauseef Jawaid
 
Case control studies
Case control studiesCase control studies
Case control studiesBruno Mmassy
 
Research Methodology - Case control study
Research Methodology - Case control studyResearch Methodology - Case control study
Research Methodology - Case control studyRizwan S A
 
Meta analysis techniques in epidemiology
Meta analysis techniques in epidemiologyMeta analysis techniques in epidemiology
Meta analysis techniques in epidemiologyBhoj Raj Singh
 
Case Control Studies
Case Control StudiesCase Control Studies
Case Control StudiesRachel Walden
 
Case control studies
Case control studiesCase control studies
Case control studiesRam Arya
 
Epidemiological study designs
Epidemiological study designsEpidemiological study designs
Epidemiological study designsIsmail Qamar
 
How to calculate Sample Size
How to calculate Sample SizeHow to calculate Sample Size
How to calculate Sample SizeMNDU net
 
Case control study
Case control studyCase control study
Case control studyTimiresh Das
 
Study designs in epidemiology
Study designs in epidemiologyStudy designs in epidemiology
Study designs in epidemiologyBhoj Raj Singh
 
Ethical Considerations in Public Health
Ethical Considerations in Public HealthEthical Considerations in Public Health
Ethical Considerations in Public HealthDr Ghaiath Hussein
 
Non randomized controlled trial
Non randomized controlled trial Non randomized controlled trial
Non randomized controlled trial HimikaRathi
 

What's hot (20)

Confounding and Directed Acyclic Graphs
Confounding and Directed Acyclic GraphsConfounding and Directed Acyclic Graphs
Confounding and Directed Acyclic Graphs
 
Meta analysis ppt
Meta analysis pptMeta analysis ppt
Meta analysis ppt
 
Metanalysis Lecture
Metanalysis LectureMetanalysis Lecture
Metanalysis Lecture
 
Bias, confounding and fallacies in epidemiology
Bias, confounding and fallacies in epidemiologyBias, confounding and fallacies in epidemiology
Bias, confounding and fallacies in epidemiology
 
Association causation
Association causationAssociation causation
Association causation
 
Case control studies
Case control studiesCase control studies
Case control studies
 
Research Methodology - Case control study
Research Methodology - Case control studyResearch Methodology - Case control study
Research Methodology - Case control study
 
Meta analysis techniques in epidemiology
Meta analysis techniques in epidemiologyMeta analysis techniques in epidemiology
Meta analysis techniques in epidemiology
 
Epidemiology Study Design
Epidemiology Study DesignEpidemiology Study Design
Epidemiology Study Design
 
Case Control Studies
Case Control StudiesCase Control Studies
Case Control Studies
 
Case control studies
Case control studiesCase control studies
Case control studies
 
Epidemiological study designs
Epidemiological study designsEpidemiological study designs
Epidemiological study designs
 
Standerdization
StanderdizationStanderdization
Standerdization
 
How to calculate Sample Size
How to calculate Sample SizeHow to calculate Sample Size
How to calculate Sample Size
 
Case control study
Case control studyCase control study
Case control study
 
Cross sectional study
Cross sectional studyCross sectional study
Cross sectional study
 
Study designs in epidemiology
Study designs in epidemiologyStudy designs in epidemiology
Study designs in epidemiology
 
Meta analysis
Meta analysisMeta analysis
Meta analysis
 
Ethical Considerations in Public Health
Ethical Considerations in Public HealthEthical Considerations in Public Health
Ethical Considerations in Public Health
 
Non randomized controlled trial
Non randomized controlled trial Non randomized controlled trial
Non randomized controlled trial
 

Similar to Analysis and Interpretation

Statistics in meta analysis
Statistics in meta analysisStatistics in meta analysis
Statistics in meta analysisDr Shri Sangle
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011NES
 
Biostatistics clinical research & trials
Biostatistics clinical research & trialsBiostatistics clinical research & trials
Biostatistics clinical research & trialseclinicaltools
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slidesBartsMSBlog
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papersBartsMSBlog
 
bio statistics for clinical research
bio statistics for clinical researchbio statistics for clinical research
bio statistics for clinical researchRanjith Paravannoor
 
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptIntroduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptAnnaMarieAndalRanill
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test SelectionVaggelis Vergoulas
 
2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - FinalBrian Lin
 
Analytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataAnalytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataCTSI at UCSF
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Isla Kuhn
 
Importance of evidence
Importance of evidenceImportance of evidence
Importance of evidencesahughes
 
Research methods 2 operationalization &amp; measurement
Research methods 2   operationalization &amp; measurementResearch methods 2   operationalization &amp; measurement
Research methods 2 operationalization &amp; measurementattique1960
 
Quantitative_analysis.ppt
Quantitative_analysis.pptQuantitative_analysis.ppt
Quantitative_analysis.pptmousaderhem1
 
25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.ppt25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.pptPriyankaSharma89719
 

Similar to Analysis and Interpretation (20)

Statistics in meta analysis
Statistics in meta analysisStatistics in meta analysis
Statistics in meta analysis
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
 
Biostatistics clinical research & trials
Biostatistics clinical research & trialsBiostatistics clinical research & trials
Biostatistics clinical research & trials
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slides
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papers
 
bio statistics for clinical research
bio statistics for clinical researchbio statistics for clinical research
bio statistics for clinical research
 
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptIntroduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test Selection
 
Meta analysis with R
Meta analysis with RMeta analysis with R
Meta analysis with R
 
2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final
 
Analytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataAnalytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational Data
 
Bgy5901
Bgy5901Bgy5901
Bgy5901
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
 
Displaying your results
Displaying your resultsDisplaying your results
Displaying your results
 
Bias and validity
Bias and validityBias and validity
Bias and validity
 
Importance of evidence
Importance of evidenceImportance of evidence
Importance of evidence
 
Research methods 2 operationalization &amp; measurement
Research methods 2   operationalization &amp; measurementResearch methods 2   operationalization &amp; measurement
Research methods 2 operationalization &amp; measurement
 
Quantitative_analysis.ppt
Quantitative_analysis.pptQuantitative_analysis.ppt
Quantitative_analysis.ppt
 
Session1b.ppt
Session1b.pptSession1b.ppt
Session1b.ppt
 
25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.ppt25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.ppt
 

More from Francisco J Grajales III

Patient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingPatient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingFrancisco J Grajales III
 
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Francisco J Grajales III
 
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsMulti-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsFrancisco J Grajales III
 
Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Francisco J Grajales III
 
Las TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláLas TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláFrancisco J Grajales III
 
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...Francisco J Grajales III
 
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Francisco J Grajales III
 
E-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengE-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengFrancisco J Grajales III
 
eHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaeHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaFrancisco J Grajales III
 
ICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthFrancisco J Grajales III
 
Electronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesElectronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesFrancisco J Grajales III
 
Interoperability Standards: The Key to Mobile Data
Interoperability Standards:The Key to Mobile DataInteroperability Standards:The Key to Mobile Data
Interoperability Standards: The Key to Mobile DataFrancisco J Grajales III
 
Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Francisco J Grajales III
 
Role of standards, consumer education and media literacy
Role of standards, consumer education and media literacyRole of standards, consumer education and media literacy
Role of standards, consumer education and media literacyFrancisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 

More from Francisco J Grajales III (20)

Patient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingPatient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharing
 
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
 
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsMulti-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
 
Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers
 
Las TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláLas TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas allá
 
Panorama Internacional del eHealth
Panorama Internacional del eHealthPanorama Internacional del eHealth
Panorama Internacional del eHealth
 
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
 
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
 
Forumclinic Reshape 09
Forumclinic Reshape 09Forumclinic Reshape 09
Forumclinic Reshape 09
 
E-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengE-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica Boateng
 
eHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaeHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in Africa
 
ICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-Health
 
Electronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesElectronic Health Records Global Perspectives
Electronic Health Records Global Perspectives
 
Interoperability Standards: The Key to Mobile Data
Interoperability Standards:The Key to Mobile DataInteroperability Standards:The Key to Mobile Data
Interoperability Standards: The Key to Mobile Data
 
Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...
 
Role of standards, consumer education and media literacy
Role of standards, consumer education and media literacyRole of standards, consumer education and media literacy
Role of standards, consumer education and media literacy
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 

Recently uploaded

How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerThousandEyes
 
What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?Antenna Manufacturer Coco
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...Martijn de Jong
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...DianaGray10
 
HTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation StrategiesHTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation StrategiesBoston Institute of Analytics
 
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Miguel Araújo
 
[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdfhans926745
 
Tech Trends Report 2024 Future Today Institute.pdf
Tech Trends Report 2024 Future Today Institute.pdfTech Trends Report 2024 Future Today Institute.pdf
Tech Trends Report 2024 Future Today Institute.pdfhans926745
 
GenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day PresentationGenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day PresentationMichael W. Hawkins
 
GenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdfGenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdflior mazor
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processorsdebabhi2
 
Understanding Discord NSFW Servers A Guide for Responsible Users.pdf
Understanding Discord NSFW Servers A Guide for Responsible Users.pdfUnderstanding Discord NSFW Servers A Guide for Responsible Users.pdf
Understanding Discord NSFW Servers A Guide for Responsible Users.pdfUK Journal
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfsudhanshuwaghmare1
 
🐬 The future of MySQL is Postgres 🐘
🐬  The future of MySQL is Postgres   🐘🐬  The future of MySQL is Postgres   🐘
🐬 The future of MySQL is Postgres 🐘RTylerCroy
 
Partners Life - Insurer Innovation Award 2024
Partners Life - Insurer Innovation Award 2024Partners Life - Insurer Innovation Award 2024
Partners Life - Insurer Innovation Award 2024The Digital Insurer
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProduct Anonymous
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationSafe Software
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoffsammart93
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAndrey Devyatkin
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptxHampshireHUG
 

Recently uploaded (20)

How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?What Are The Drone Anti-jamming Systems Technology?
What Are The Drone Anti-jamming Systems Technology?
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
HTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation StrategiesHTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation Strategies
 
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
 
[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf[2024]Digital Global Overview Report 2024 Meltwater.pdf
[2024]Digital Global Overview Report 2024 Meltwater.pdf
 
Tech Trends Report 2024 Future Today Institute.pdf
Tech Trends Report 2024 Future Today Institute.pdfTech Trends Report 2024 Future Today Institute.pdf
Tech Trends Report 2024 Future Today Institute.pdf
 
GenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day PresentationGenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day Presentation
 
GenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdfGenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdf
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processors
 
Understanding Discord NSFW Servers A Guide for Responsible Users.pdf
Understanding Discord NSFW Servers A Guide for Responsible Users.pdfUnderstanding Discord NSFW Servers A Guide for Responsible Users.pdf
Understanding Discord NSFW Servers A Guide for Responsible Users.pdf
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
 
🐬 The future of MySQL is Postgres 🐘
🐬  The future of MySQL is Postgres   🐘🐬  The future of MySQL is Postgres   🐘
🐬 The future of MySQL is Postgres 🐘
 
Partners Life - Insurer Innovation Award 2024
Partners Life - Insurer Innovation Award 2024Partners Life - Insurer Innovation Award 2024
Partners Life - Insurer Innovation Award 2024
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
04-2024-HHUG-Sales-and-Marketing-Alignment.pptx
 

Analysis and Interpretation

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Risk ratio (RR) aka relative risk RR = a / (a+b) c / (c+d) Risk/ probability/ chance of the occurrence of an event in treatment relative to control Intervention Control a+b=n I c+d=n C Event No event d c b a
  • 8. Sample RR Calculation Death No death RR = 14/133 = 0.11 = 0.13 128/148 0.86 Drug 133 148 Placebo 20 128 119 14
  • 9. Odds ratio (OR) Intervention Control No event Event OR = a / b c / d Odds of an event occurring to it not occurring for treatment relative to control a+b=n I c+d=n C d c b a
  • 10. Sample OR Calculation Death No death Drug Placebo 133 148 OR = 14/119 = 0.12 = 0.019 128/20 6.4 20 128 119 14
  • 11. Interpreting (for intervention) Increased odds (harmful) Increased odds (beneficial) OR>1 (6.4/0.12) Reduced odds (beneficial) Reduced odds (not beneficial) OR<1 (0.12/6.4) No difference No difference OR=1, RR=1 Increased risk (harmful) Increased risk (beneficial) RR>1 (0.86/0.11) Reduced risk (beneficial) Reduced risk (not beneficial) RR<1 (0.11/0.86) Bad outcome (e.g. infection) Good outcome (e.g. remission)
  • 12.
  • 13. Closer Look at Odds RR = 0.11 / 0.86 = 0.13 ↑ A rate (11%) OR = 0.12 / 6.4 = 0.019 ↑ ~1:9 ↑ ~7:1
  • 14.
  • 15. Risk Difference (RD) Death No death Actual difference in risk of events Placebo Drug 133 148 RD = 14/133 – 128/148 = 0.11 – 0.86 = - 0.75 20 128 119 14
  • 16.
  • 17.
  • 18.
  • 19.
  • 21.
  • 22.
  • 23. Fixed Effects Analysis in Picture View
  • 24. Random Effects Analysis in Picture View
  • 25. Random effects in RevMan 5 ← DerSimonian and Laird random effects model
  • 26. Random effects in RevMan 5 (continued) ← DerSimonian and Laird random effects model
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36. I 2 Statistic (continued) * Importance of I 2 value depends on: ● magnitude and direction of effects ● strength of evidence of heterogeneity - Chi-squared P value, or - I 2 confidence interval Considerable heterogeneity* 75% to 100% May represent substantial heterogeneity* 50% to 90% May represent moderate heterogeneity* 30% to 60% Might not be important 0% to 40% Guide to Interpretation I 2 value
  • 37. Sample Forest Plot: Q and I 2
  • 38.
  • 39.
  • 40.
  • 42.